Metabolic and Bariatric Surgery for People Living With HIV—A Propensity-Matched Cohort Study DOI
Erik Stenberg, Christina Carlander, Yang Cao

и другие.

JAIDS Journal of Acquired Immune Deficiency Syndromes, Год журнала: 2023, Номер 94(3), С. e5 - e8

Опубликована: Окт. 18, 2023

Stenberg, Erik MD, PhDa; Carlander, Christina PhDb,c; Cao, Yang PhDd,e; Ottosson, Johan Näslund, PhDf Author Information

Язык: Английский

Pharmacokinetics after bariatric surgery: adverse effects and drug safety issues in bariatric patients DOI

Daniel Porat,

Arik Dahan

Expert Review of Clinical Pharmacology, Год журнала: 2025, Номер unknown, С. 1 - 8

Опубликована: Янв. 31, 2025

Introduction Medication management after bariatric surgery is a major and complex challenge. The altered gastrointestinal anatomy/physiology post-surgery may impact oral drug absorption/pharmacokinetics, with potential clinical implications. Along multiple studies/cases of impaired leading to treatment failure, reports increased exposure, post-bariatric safety issues adverse effects risk, are also available; yet, this second scenario levels, less familiar in practice.

Язык: Английский

Процитировано

1

The Effects of Bariatric Surgery on Pharmacokinetics of Drugs: a Review of Current Evidence DOI Creative Commons
Sofia Konstantinidou, Georgia Argyrakopoulou, Μaria Dalamaga

и другие.

Current Nutrition Reports, Год журнала: 2023, Номер 12(4), С. 695 - 708

Опубликована: Окт. 20, 2023

Abstract Purpose of Review Obesity constitutes a major public health concern and has been recognized as an epidemic. To date, bariatric surgery remains the most effective way for substantial long-lasting weight loss in severe obesity. The purpose this review is to summarize how pharmacokinetics drugs are affected by common types surgery, i.e., Roux-en-Y gastric bypass (RYGB) sleeve gastrectomy (SG). Recent Findings Limited data available regarding changes after surgery. lack existing guidelines may lead patients experience drug toxicity or therapeutic undertreatment. Pharmacokinetic parameters that need be taken into consideration postoperatively include motility, volume, pH, surface area, bile secretions, carrier proteins, first-pass metabolism. For with narrow index, other factors monitored closely, including plasma levels, patients’ clinical outcomes, laboratory markers. Patients should followed up frequently treated accordance their response therapy. Summary Bariatric affect various drugs, due resultant anatomical loss. Therefore, there identify those potential adjust medication doses order achieve higher efficacy avoid toxicity.

Язык: Английский

Процитировано

16

Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics DOI

Daniel Porat,

Oleg Dukhno,

Mazal Partook-Maccabi

и другие.

International Journal of Pharmaceutics, Год журнала: 2023, Номер 645, С. 123347 - 123347

Опубликована: Авг. 24, 2023

Язык: Английский

Процитировано

10

Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions DOI
Dario Cattaneo, Cristina Gervasoni

Expert Review of Clinical Pharmacology, Год журнала: 2024, Номер 17(7), С. 579 - 587

Опубликована: Июнь 3, 2024

Introduction The treatment of HIV infection has been revolutionized in recent years thanks to the advent dual antiretroviral regimens, administered orally or as long-acting injectable formulations. Here, we provide an update on usefulness therapeutic drug monitoring (TDM) drugs optimize management people with (PWH) current scenario.

Язык: Английский

Процитировано

4

Intracellular tenofovir‐diphosphate concentrations in HIV pre‐exposure prophylaxis users who underwent bariatric surgery DOI Creative Commons
Matthew W McGarrity, Paul MacPherson,

A Li

и другие.

HIV Medicine, Год журнала: 2025, Номер unknown

Опубликована: Янв. 15, 2025

To measure concentrations of tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) among individuals taking disoproxil fumarate plus emtricitabine (TDF/FTC) or alafenamide (TAF/FTC) who were scheduled to undergo had already undergone bariatric surgery. We enrolled pre-exposure prophylaxis (PrEP) users attending clinics Toronto Ottawa undergoing After participants completed a minimum 7 days consecutive PrEP dosing, we collected DBS samples immediately before they administered their next daily dose PrEP. Participants surgery enrolment provided single sample at baseline only. One participant planned preoperatively and on postoperative 7, 28 84. TFV-DP was measured by liquid chromatography tandem mass spectrometry. compared results against the population range varying degrees adherence stratified chronology surgery, type regimen. Of seven eligible participants, all gay, cis-gender men. Median age 48 years (Q1-Q3: 44-51). Six underwent enrolment: four Roux-en-Y gastric bypass (RYGB) two sleeve gastrectomy (SG). Four TDF/FTC TAF/FTC. All therapeutic concentrations, except for one SG. TAF/FTC receiving RYGB displayed slight decrease over time, although remained range. Tenofovir near values this small men using oral

Язык: Английский

Процитировано

0

Long-acting injectable antiretroviral therapy: potential solution for postbariatric surgery challenges DOI

Jacopo Testa,

Dario Cattaneo, Andrea Giacomelli

и другие.

AIDS, Год журнала: 2025, Номер 39(5), С. 625 - 626

Опубликована: Март 13, 2025

Testa, Jacopo; Cattaneo, Dario; Giacomelli, Andrea; Lai, Alessia; Ridolfo, Anna Lisa; Gori, Menzaghi, Barbara; Gervasoni, Cristina Author Information

Язык: Английский

Процитировано

0

Diabetes in HIV: the Link to Weight Gain DOI
Samuel Bailin, John R. Koethe

Current HIV/AIDS Reports, Год журнала: 2022, Номер 20(1), С. 9 - 18

Опубликована: Ноя. 23, 2022

Язык: Английский

Процитировано

14

GLP‐1 agonists for people living with HIV and obesity, is there a potential? DOI
Leena Zino, Cees J. Tack, Olivier Richel

и другие.

HIV Medicine, Год журнала: 2023, Номер 24(10), С. 1029 - 1034

Опубликована: Июнь 20, 2023

Abstract Background and objectives Obesity trends metabolic dysregulation are rising in people living with HIV using antiretrovirals (ARVs). Underlying causes preventive strategies being investigated. Two glucagon like‐peptide 1 (GLP‐1) agonists, liraglutide semaglutide, were formerly approved as glucose‐lowering drugs have been recently for long‐term weight loss obesity. Due to the lack of therapeutic guidelines or clinical trials HIV, we discuss potential benefits, safety aspects pharmacological considerations prescribing semaglutide HIV. Results Clinical experience is limited two cases diabetic after which a successful glycaemic control observed. None adverse events associated usage indicate an additional risk Extra caution showed be warranted when initiating GLP‐1 agonist therapy taking protease inhibitors who pre‐existing factors heart rate variability reduce incidence RP interval prolongation. agonists metabolized by endopeptidases, thus do not generate major drug–drug interactions most drugs, including ARVs. GLP‐s known inhibit gastric acid secretion, warrants close monitoring combined atazanavir oral rilpivirine, ARVs that require low pH optimal absorption. Conclusion Theoretical few available observations support prescription with, far, no indications concern regarding efficacy,

Язык: Английский

Процитировано

7

Outcomes of Bariatric Surgery in People With Human Immunodeficiency Virus: A Retrospective Analysis From the ATHENA Cohort DOI Creative Commons
Leena Zino,

Ferdinand Wit,

Casper Rokx

и другие.

Clinical Infectious Diseases, Год журнала: 2023, Номер 77(11), С. 1561 - 1568

Опубликована: Июнь 30, 2023

Abstract Background The implications of bariatric surgery (BS) on virologic and metabolic outcomes in people with human immunodeficiency virus (HIV; PWH) antiretroviral therapy (ART) are unknown. Methods Here, we report a retrospective analysis up to 18 months post-BS PWH from the AIDS Therapy evaluation Netherlands (ATHENA) cohort data all dutch HIV treating Centers. Primary end points were confirmed failure (2 consecutive HIV-RNA measurements >200 copies/mL) percentage patients who achieved >20% total body weight loss post-BS. Switches baseline ART trough plasma concentrations antiretrovirals also reported Metabolic parameters medication usage compared pre- Results Fifty-one included. One case 3 cases viral blips detected this Eighty-five percent at post-BS, mean difference (95% confidence interval) −33.5% (−37.7% −29.3%). Trough measured agents above minimum effective concentrations, except for 1 sample darunavir. Lipid profiles, but not serum creatinine blood pressure, improved significantly (P < .01) Total medications obesity-related comedications declined 203 103 62 25, respectively, Conclusions BS was an intervention lipid control using no clear link poor outcomes.

Язык: Английский

Процитировано

4

Five-Year Outcomes of Bariatric Surgery vs. Conservative Weight Management in People with HIV: A Single-Center Tertiary Care Experience DOI Creative Commons
Matyas Fehervari, Anuja T. Mitra, Narek Sargsyan

и другие.

Obesity Surgery, Год журнала: 2024, Номер 34(10), С. 3594 - 3605

Опубликована: Авг. 27, 2024

Individuals with human immunodeficiency virus (HIV) infection now have life expectancies similar to non-infected people but face increased obesity prevalence. The long-term effects of bariatric surgery (BS) and conservative weight therapy (CWT) in patients living HIV (PLWH) remain unexplored.

Язык: Английский

Процитировано

0